47.73.Z - Retail sale of pharmaceutical products
20.13.Z - Manufacture of other inorganic basic chemicals
20.14.Z - Manufacture of other organic basic chemicals
20.59.Z - Manufacture of other chemical products, not elsewhere classified
21.10.Z - Manufacture of basic pharmaceutical products
21.20.Z - Manufacture of pharmaceutical preparations and other pharmaceutical products
47.74.Z - Retail sale of medical and orthopedic products
64.92.Z - Other forms of credit granting
64.99.Z - Other financial services, except insurance and pension funds, not elsewhere classified
66.19.Z - Other activities supporting financial services, excluding insurance and pension funds
2021 | 2022 | 2023 | ||
---|---|---|---|---|
M PLN | M PLN | M PLN | % | |
Gross profit (loss) | 0,9 | 0,9 | 1,5 | 67,5 |
EBITDA | 1,8 | 2,3 | 3,3 | 40,8 |
Short time liabilities | 26,8 | 27,7 | 29,6 | 6,8 |
Equity capital | 11,9 | 0,7 | 2,2 | 208 |
Operating profit (EBIT) | 1,3 | 1,9 | 2,8 | 51,1 |
Assets | 39,8 | 29,3 | 33,2 | 13,4 |
Net profit (loss) | 0,7 | 0,8 | 1,5 | 79,9 |
Cash | 2,4 | 2,8 | 2,6 | -7,4 |
Net income from sale | 73,8 | 85,3 | 88,9 | 4,3 |
Liabilities and provisions for liabilities | 27,9 | 28,6 | 31 | 8,5 |
Working assets | 17,9 | 20,1 | 24 | 19,1 |
Depreciation | 0,5 | 0,4 | 0,4 | -2,7 |
% | % | % | p.p. | |
Profitability of capital | 6,1 | 115,6 | 67,5 | -48,1 |
Equity capital to total assets | 29,8 | 2,5 | 6,7 | 4,2 |
Gross profit margin | 1,3 | 1,1 | 1,7 | 0,6 |
EBITDA Margin | 2,4 | 2,7 | 3,7 | 1 |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 133 | 119 | 122 | 3 |
Current financial liquidity indicator | 0.665675163269043 | 0.7260956764221191 | 0.808651328086853 | 0,1 |
Net dept to EBITDA | 4.470991134643555 | 2.3969342708587646 | 1.653165578842163 | -0,7 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane